|
Implementing Early Intervention Services for Clinical High Risk for Psychosis in U.S. Community Settings: What Do We Know and What Do We Need to Know?
|
Meeting/ Workshop
|
SAMHSA
|
NIMH
|
NIMH collaborated with the Substance Abuse and Mental Health Services Administration (SAMHSA) in sponsoring this research meeting on July 27-28, 2017 in Bethesda, MD. The purpose of this meeting was to lay the groundwork for developing a national strategy to expand services for early psychosis to include evidence-based interventions for clinical high-risk states. Leading researchers in this field presented findings on the effectiveness of clinical high-risk interventions and directors of clinical programs presented on the challenges and opportunities in implementing these services in communities.
|
|
Improving Genomics/Omics Technical Standards and Molecular Tools for Prebiotic Probiotic Research and Development Working Group
|
Research Initiative
|
CDC, FDA, OS
|
NCCIH, NCI, NHGRI, NIDA, NLM
|
The overarching workgroup effort is to enhance research initiatives/resource development as IAA workgroup members committed to sustain and accelerate translatability of validation analytics and reference datasets using omic and other multi-omic substitutable [SMART] tools, devices, and HL-7 FHIR technologies to support rapid and efficient interoperability with electronic health records and clinical decision support systems. A second goal is to coordinate and plan trans-NIH and Inter-agency meetings, workshops and initiatives with greater efficiency of ICO resources and expertise between agencies. Innovative technologies like HL-7 SMART on FHIR have been demonstrated to enhance health information exchange, affordably and accurately. Novel device monitoring using reference standards including, FDA Precision and NIST nanofabrication, multi-omics and modeling strategies can be integrated to improve validation and standards biosafety, risk monitoring of adverse drug events, food safety, overuse and resistance to antibiotics, and emerging infection. The intent originated in April 2016 with an Initiative planning meeting that is now ongoing for IAA partnered PCORI; other IAA collaboratives in progress.
|
|
Improving steps in development and assessment of Fecal Microbiota for Transplantation products
|
Other
|
FDA
|
NIAID
|
The goals are to (1) examine the utility of pathogen detection methods in Fecal Microbiota for Transplantation (FMT), (2) understand the effect of manufacturing conditions on the viability and efficacy of FMT products, and (3) identify markers of potency for FMT products by leveraging a novel mouse strain (MAIT cell deficient) exhibiting unique resistance to C. difficile colonization.
|
|
Improving the Treatment for Allergic Rhinoconjunctivitis and Asthma Through Allergen Immunotherapy
|
Other
|
AHRQ
|
NIAID
|
NIAID and AHRQ collaborated in organizing a June 2015 workshop entitled “Improving the Treatment for Allergic Rhinoconjunctivitis and Asthma Through Allergen Immunotherapy." The goal of this meeting was to develop clinical trial protocols that could address some of the identified needs to improve the effectiveness of allergen immunotherapy, and to identify the need to improve the use of allergen immunotherapy in current medical practice. Two manuscripts, summarizing the workshop discussion and recommendations, are in preparation.
|
|
Inclusion Across the Lifespan
|
Meeting/ Workshop
|
FDA
|
NIA, NCI, NHLBI, NICHD, NIDCR, NIMHD, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH, OD/OER
|
In response to scientific need and a congressional mandate in the 21st Century Cures Act (P.L. 114-255), the National Institutes of Health (NIH) convened a workshop of experts on the appropriate inclusion of pediatric and older populations in research studies involving human subjects. The workshop brought together experts in clinical research to discuss barriers and opportunities for participation of these populations in clinical studies, including those supported by NIH.
|
|
Influenza Risk Management Meeting
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
NIAID
|
The Influenza Risk Management Meetings provide members (including ASPR/BARDA, CDC, FDA, and NIH) with a venue to discuss issues relating to the US Department of Health and Human Services (HHS) response to pandemic influenza. Subjects for discussion include but are not limited to considerations of vaccine and antiviral stockpiles and clinical trial response to influenza outbreaks such as H7N9 and H3N2v.
|
|
Influenza Vaccine Manufacturing Improvement Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
NIAID
|
The Influenza Vaccine Manufacturing Improvement Group aims to optimize donor strains, improve sterility assays, and develop alternative potency assays.
|
|
Intelligent Robotics and Autonomous Systems (IRAS) Interagency Working Group
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, OS
|
NICHD, NEI, NIA, NIBIB, NINDS, NINR
|
The IRAS Interagency Working Group coordinates Networking and Information Technology Research and Development (NITRD) Program research and development programs, budgets, and policy recommendations, focusing on the advancement of intelligent robotics and autonomous systems that complement, augment, enhance, or emulate human physical capabilities or embodied human intelligence. This includes identifying and pursuing current and emerging topics of mutual interest to the member agencies; launching of task forces to examine specific timely research topics and opportunities; coordinating major interagency outreach activities; and facilitating the development and sharing of data, models, software tools, and testbeds among NITRD agencies and stakeholders.
|
|
Inter-Agency Working Group on Technology Transfer
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
OD/OIR/OTT, OD/OIR
|
This working group recommends opportunities for improving technology transfer (TT) from Federal laboratories, including: (1) current technology transfer programs and standards for assessing the effectiveness of these programs; (2) new or creative approaches to technology transfer that might serve as model programs for Federal laboratories; (3) criteria to assess the effectiveness and impact on the Nation''s economy of planned or future technology transfer efforts; (4) an assessment of cooperative research and development venture programs; and (5) policy and guidance statements to support all Federal Agencies'' TT programs.
|
|
Inter-Agency Working Group on the National Healthcare Quality and Disparities Report
|
Committee, Work group, Advisory group, or Task Force
|
ACF, AHRQ, CDC, CMS, HRSA, IHS, OS
|
NIMHD, NCI, NHLBI, OD/DPCPSI
|
This working group provides expert scientific guidance for the National Healthcare Quality and Disparities Report. These annual reports measure trends in effectiveness of care, patient safety, timeliness of care, patient centeredness, and efficiency of care. The reports present, in chart form, the latest available findings on quality of and access to health care.
|